Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nausea With Vomiting Chemotherapy-Induced Clear all
Completed Phase 2 Interventional Results available

Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

NCT02097823
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
Olanzapine, Aprepitant
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

NCT00440128
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Docetaxel, Casopitant/Docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Hot Springs, Arkansas • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

NCT01534637
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
Drug · Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

NCT00404378
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ketoconazole, casopitant 100 mg, Casopitant 50 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

NCT01449188
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ondansetron, moxifloxacin, saline
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Promoting Cancer Symptom Management in Older Adults

NCT03143829
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Other
Lead sponsor
University of Central Florida
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

NCT02991456
View directory record Official record
Conditions
Chemo-radiation Induced Nausea and Vomiting
Interventions
Rolapitant, Ondansetron
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 24, 2026, 5:25 AM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 24, 2026, 5:25 AM EDT
Withdrawn Not applicable Interventional

Prevention of Unmitigated Chemotherapy-induced Emesis

NCT03996863
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
Interventions
Otoband, Placebo device
Device
Lead sponsor
Otolith Labs
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 24, 2026, 5:25 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

NCT06065722
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
Akynzeo
Drug
Lead sponsor
Simon Williamson Clinic
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Mount Olive, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 24, 2026, 5:25 AM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

NCT00366834
View directory record Official record
Conditions
Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Not applicable Interventional

A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer

NCT00754286
View directory record Official record
Conditions
Brain Tumors, Leukemia, Sarcomas, Neuroblastoma, Lymphoma, Hodgkins Disease
Interventions
Aromatherapy Scented Wand, Placebo wand
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
7 Years to 21 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 24, 2026, 5:25 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

NCT01031953
View directory record Official record
Conditions
Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fosaprepitant dimeglumine, systemic chemotherapy, survey administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

NCT00642512
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
dronabinol, ondansetron, dronabinol/ondansetron, placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
43
States / cities
Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

NCT01500226
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
565
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

NCT01363479
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Oral palonosetron, I.V. palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Jul 24, 2026, 5:25 AM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

NCT01499849
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jul 24, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Jul 24, 2026, 5:25 AM EDT
Not yet recruiting No phase listed Observational

Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy

NCT07374939
View directory record Official record
Conditions
Nausea and Vomiting Chemotherapy-Induced
Interventions
Medical Cannabis
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 24, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00895245
View directory record Official record
Conditions
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy
Drug · Other · Behavioral + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Jul 24, 2026, 5:25 AM EDT